PATH and MMV launch 5-year global initiative to support elimination of relapsing malaria
Retrieved on:
Tuesday, April 23, 2019
GENEVA and SEATTLE, April 23, 2019 /PRNewswire/ -- PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria.
Key Points:
- GENEVA and SEATTLE, April 23, 2019 /PRNewswire/ -- PATH and Medicines for Malaria Venture (MMV) announce a 5-year, jointly-led initiative, VivAccess, to support countries in the elimination of Plasmodium vivax (P. vivax) malaria.
- VivAccess is set to accelerate their access to those in need and in doing so protect patients from relapses and support countries to move towards malaria elimination."
- In the process, the initiative will strengthen national and local capacities in alignment with the WHO malaria strategic agenda .
- "Relapsing malaria due to Plasmodium vivax is the most geographically widespread malaria, with well over 2 billion people living in areas of risk for infection, said Dr. Larry Slutsker , Director of the PATH Center for Malaria Control and Elimination.